L
Lepu Biopharma / 乐普生物
HK-listed oncology biologics — ADCs, IO and oncolytic virus platforms
About Lepu Biopharma / 乐普生物
Shanghai HK-listed oncology biologics OEM (Lepu Biopharma / 乐普生物; HKEX 2157) develops ADC platforms plus oncolytic-virus and immuno-oncology adjacency with end-to-end discovery-to-GMP manufacturing for China and partnered ex-China channels. Founded in 2018 and operating from Shanghai with Beijing manufacturing adjacency, the company commercializes oncology assets such as pucotenlimab while advancing ADC and IO clinical programs. Mid-size China ADC leftover beyond Mabwell FIX this pack and Pack 42 RemeGen FIX / Duality softer profiles.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2022 | $116M | $116M | Undisclosed | ↗ |
| SERIES BOther financing | Aug 2020 | $1.3B | $5.2B | Ping An Group · Chinese Reform Holdings Corporation · SDIC Unity Capital · Ping An Capital | ↗ |
Growth signals
Latest recorded traffic for Lepu Biopharma / 乐普生物 is 390 monthly website visits, up 69.6% over the last three months. Lepu Biopharma / 乐普生物's team grew 6.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lepu Biopharma / 乐普生物 in its local ecosystem
The Lepu Biopharma / 乐普生物 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Ping An Capital
Ping An Group- CCChinese Reform Holdings Corporation
SDIC Unity Capital
Haitong Innovation Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lepu Biopharma / 乐普生物 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lepu Biopharma / 乐普生物’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









